

Substitute for Form PTO-1390		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER <div style="text-align: right; font-weight: bold;">034548-001</div>	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <div style="text-align: right; font-weight: bold;">10/559,431</div>	
INTERNATIONAL APPLICATION NO. <div style="text-align: center;">PCT/FR2004/050214</div>		INTERNATIONAL FILING DATE <div style="text-align: center;">04 June 2004 (04.06.2004)</div>		PRIORITY DATE CLAIMED <div style="text-align: center;">05 June 2003 (05.06.2003)</div>	
TITLE OF INVENTION COMPOSITION COMPRISING THE POLYPROTEIN NS3/NS4 AND THE POLYPEPTIDE NS5B OF HCV, EXPRESSION VECTORS INCLUDING THE CORRESPONDING NUCLEIC SEQUENCES AND THEIR THERAPEUTIC USE (As Amended)					
APPLICANT(S) FOR DO/EO/US Anne FOURNILLIER, Genevieve INCHAUSPE, Jean-Daniel ABRAHAM, Maria DIMITROVA-TCHOMAKOV and Marie PARNOT					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
1. <input type="checkbox"/> This is a FIRST submission to items concerning a filing under 35 U.S.C. 371. 2. <input checked="" type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (22) indicated below. 4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31). 5. <input type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)) a. <input type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).					
Items 11 to 21 below concern document(s) or information included:					
11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input type="checkbox"/> A FIRST preliminary amendment. 14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A change of power of attorney and/or address letter. 17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 C.F.R. 1.821 - 1.825. 18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. <input checked="" type="checkbox"/> Other items or information: <u>Combined Declaration and Power of Attorney</u> <hr/> <hr/> <hr/> <hr/>					

U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <div style="text-align: center;">10/559,431</div>	INTERNATIONAL APPLICATION NO. <div style="text-align: center;">PCT/FR2004/050214</div>	ATTORNEY'S DOCKET NUMBER <div style="text-align: center;">034548-001</div>
--	---	---

21. <input checked="" type="checkbox"/> Applicant(s) requests that the published application include the following assignment information: <u>TRANSGENE S.A., Strasbourg, France, and INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, Paris Cedex 13, France.</u> 	CALCULATIONS PTO USE ONLY
--	--

22. <input type="checkbox"/> The following fees are submitted:			
Basic Filing Fee (1631)		\$ 0.00	
Surcharge of \$130.00 (1617) for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).			
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE \$
Total Claims	-20 =	0	x \$50.00 (1615) \$ 0.00
Independent Claims	- 3 =	0	x \$200.00 (1614)
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$360.00 (1616)
Examination Fee			+ \$200.00 (1633) \$ 0.00
Search Fee			+ \$400.00 (1632) \$ 0.00
App. Size Fee (add \$250.00 for each add'l 50 sheets exceeding 100 sheets)			
TOTAL OF ABOVE CALCULATIONS =			
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.			+ \$ 0.00
SUBTOTAL =			\$ 0.00
Processing fee of \$130.00 (1618) for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).			\$ 0.00
TOTAL NATIONAL FEE =			\$ 0.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 (8021) per property +			
TOTAL FEES ENCLOSED =			\$ 0.00
			Amount to be refunded :
			charged :


a. ☐ A check in the amount of _____ to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. 02-4800 in the amount of _____ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-4800. A duplicate copy of this sheet is enclosed.

d. ☐ Charge _____ to credit card. Form PTO-2038 is attached.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO: Buchanan Ingersoll PC Including attorneys from Burns, Doane, Swecker & Mathis P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620	 SIGNATURE Susan M. Dadio NAME <div style="display: flex; justify-content: space-between;"> 40,373 December 5, 2005 </div> <div style="display: flex; justify-content: space-between;"> REGISTRATION NO. DATE </div>
---	--